Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Combined with S-1 in Refractory Nasopharyngeal Carcinoma
NCT06657690Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 1 year. Started Nov 2024; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06657690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06657690.